Denali Therapeutics Inc (DNLI) — Cash Flow Quality Index
Denali Therapeutics Inc (DNLI) has a Cash Flow Quality Index of -0.62x as of June 2023. Operating cash flow of $-113.17 Million is below net income of $183.38 Million, suggesting accrual-heavy earnings not yet converted to cash. Explore DNLI long-term investment intensity to see how much of total assets are deployed in long-term investments.
Cash Flow Quality Index
Operating Cash Flow
Net Income
Data as of
Denali Therapeutics Inc Cash Flow Quality Index (2020–2020)
Historical Cash Flow Quality Index for Denali Therapeutics Inc across 1 annual periods. Values consistently above 1.0x indicate high-quality earnings. Check Denali Therapeutics Inc tangible net worth ratio to evaluate the tangible quality of the company's equity base.
Annual Cash Flow Quality Index for Denali Therapeutics Inc (2020–2020)
Year-by-year earnings quality comparison for Denali Therapeutics Inc. For live market cap and the full company financial profile, see DNLI stock market capitalisation.
| Year | Quality Index | Operating CF (USD) | Net Income | YoY Change |
|---|---|---|---|---|
| 2020 | 5.85x | $416.15 Million | $71.14 Million | — |